Redeye provides an update on Scandinavian ChemoTech following the strong Q1 2024 report. Net sales came in 77% above our estimates, at cSEK1.3m, and the cost control from the company was impressive. We increase our sales estimates, lower the cost base slightly, and increase our valuation.
LÄS MER